Literature DB >> 10485081

Robust optimal design for the estimation of hyperparameters in population pharmacokinetics.

M Tod1, F Mentré, Y Merlé, A Mallet.   

Abstract

The expectation of the determinant of the inverse of the population Fisher information matrix is proposed as a criterion to evaluate and optimize designs for the estimation of population pharmacokinetic (PK) parameters. Given a PK model, a measurement error model, a parametric distribution of the parameters and a prior distribution representing the belief about the hyperparameters to be estimated, the EID criterion is minimized in order to find the optimal population design. In this approach, a group is defined as a number of subjects to whom the same sampling schedule (i.e., the number of samples and their timing) is applied. The constraints, which are defined a priori, are the number of groups, the size of each group and the number of samples per subject in each group. The goal of the optimization is to determine the optimal sampling times in each group. This criterion is applied to a one-compartment open model with first-order absorption. The error model is either homoscedastic or heteroscedastic with constant coefficient of variation. Individual parameters are assumed to arise from a lognormal distribution with mean vector M and covariance matrix C. Uncertainties about the M and C are accounted for by a prior distribution which is normal for M and Wishart for C. Sampling times are optimized by using a stochastic gradient algorithm. Influence of the number of different sampling schemes, the number of subjects per sampling schedule, the number of samples per subject in each sampling scheme, the uncertainties on M and C and the assumption about the error model and the dose have been investigated.

Mesh:

Year:  1998        PMID: 10485081     DOI: 10.1023/a:1020703007613

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  16 in total

1.  A computationally efficient approach for the design of population pharmacokinetic studies.

Authors:  J Wang; L Endrenyi
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

2.  Experimental design and efficient parameter estimation in population pharmacokinetics.

Authors:  M K al-Banna; A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

Review 3.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 4.  Population pharmacokinetics/dynamics.

Authors:  L B Sheiner; T M Ludden
Journal:  Annu Rev Pharmacol Toxicol       Date:  1992       Impact factor: 13.820

5.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.

Authors:  D Z D'Argenio
Journal:  Math Biosci       Date:  1990-04       Impact factor: 2.144

6.  Comparison of some practical sampling strategies for population pharmacokinetic studies.

Authors:  E N Jonsson; J R Wade; M O Karlsson
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

7.  Optimal experiment design for nonlinear models subject to large prior uncertainties.

Authors:  E Walter; L Pronzato
Journal:  Am J Physiol       Date:  1987-09

8.  Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.

Authors:  E I Ette; C A Howie; A W Kelman; B Whiting
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

9.  Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria.

Authors:  M Tod; J M Rocchisani
Journal:  Comput Methods Programs Biomed       Date:  1996-06       Impact factor: 5.428

10.  Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.

Authors:  Y Hashimoto; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1991-06
View more
  17 in total

1.  Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.

Authors:  Y Merlé; M Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

2.  Optimal design of a population pharmacodynamic experiment for ivabradine.

Authors:  S B Duffull; F Mentré; L Aarons
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

3.  Optimization of individual and population designs using Splus.

Authors:  Sylvie Retout; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

4.  Sample size computations for PK/PD population models.

Authors:  Dongwoo Kang; Janice B Schwartz; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

5.  Robust population pharmacokinetic experiment design.

Authors:  Michael G Dodds; Andrew C Hooker; Paolo Vicini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

Review 6.  A pragmatic approach to the design of population pharmacokinetic studies.

Authors:  Amit Roy; Ene I Ette
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

7.  Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial.

Authors:  Marylore Chenel; Kayode Ogungbenro; Vincent Duval; Christian Laveille; Roeline Jochemsen; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

8.  Simultaneous optimal experimental design on dose and sample times.

Authors:  Joakim Nyberg; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-03-25       Impact factor: 2.745

9.  Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.

Authors:  Marylore Chenel; François Bouzom; Leon Aarons; Kayode Ogungbenro
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-01-07       Impact factor: 2.745

10.  Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design.

Authors:  Hanna E Silber; Joakim Nyberg; Andrew C Hooker; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-25       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.